Immunotherapy for cancer

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

5 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens

4 months ago talkbio0Tagged Cryptigen, CryptoMap platform, DNA, Epitopea, heroin, Immunotherapy, Immunotherapy for cancer, Merck & Co., tumor-specific antigens

Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

5 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions

7 months ago talkbio0Tagged Immunotherapy for cancer, Keytruda, Merck, non-inferiority, Phase 3 trial, regulatory, subcutaneous, submissions

Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

7 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry

Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody

7 months ago talkbio0Tagged Antibodies, bi-functional, biotech, David Epstein, Immunotherapy for cancer, Ottimo Pharma, PD1/VEGFR2, VEGF bifunctional antibody

Ottimo Pharma, David Epstein, PD1/VEGFR2 bi-functional antibody, Cancer immunotherapy, VEGF bifunctional antibody, Biotech startup

FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy

9 months ago talkbio0Tagged Approved, atezolizumab, Enhanze drug delivery technology, Hyaluronidase-tqjs, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous, Tecentriq, United States Food and Drug Administration

Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology

Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

9 months ago talkbio0Tagged Approved, Enhanze Drug Delivery, Halozyme, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous administration, Tecentriq, Technology, United States Food and Drug Administration

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology

Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development

1 year ago1 year ago talkbio0Tagged Biotechnology, BMS, Bristol Myers Squibb, checkpoint inhibitor, Drug Development, GPR65 gene, Immunotherapy for cancer, Investments, Pathios

Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.